REFRACTORY MARGINAL ZONE LYMPHOMA
Clinical trials for REFRACTORY MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis early-stage study tests the safety and best dose of two drugs—ibrutinib and lenalidomide—given together to people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The goal is to find a dose that is safe and tolerable, while also seeing …
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:18 UTC
-
New hope for tough blood cancers: experimental drug enters human testing
Disease control OngoingThis early-stage trial tests a new drug called BGB-21447 in about 112 people whose B-cell blood cancers (like lymphoma or leukemia) have returned or stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 17, 2026 03:14 UTC
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThis study tests a treatment using a patient's own immune cells, modified in a lab to recognize and attack a protein called CD20 on lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. The goal is to find the safe…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug cocktail shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis early-phase study tests the safety and best dose of a three-drug combination (venetoclax, lenalidomide, and rituximab) in adults with follicular or marginal zone lymphoma that has returned or not responded to prior treatment. The drugs work by blocking cancer cell survival s…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New combo therapy shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis study tests a new drug called ALX148 combined with two standard treatments (rituximab and lenalidomide) for people with B-cell non-Hodgkin lymphoma that has not responded to prior therapy. The goal is to find the best dose and see if the combination can shrink or control the…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
New combo tackles tough blood cancers
Disease control OngoingThis early-phase study tests two drugs, pevonedistat and ibrutinib, together in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effects…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 04, 2026 16:32 UTC